Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar;24(3):212-228.
doi: 10.1007/s11864-023-01054-7. Epub 2023 Feb 2.

A League of Its Own? Established and Emerging Therapies in Undifferentiated Pleomorphic Sarcoma

Laurie Graves  1 , William R Jeck  2   3 , Juneko E Grilley-Olson  3   4
Affiliations
Review

A League of Its Own? Established and Emerging Therapies in Undifferentiated Pleomorphic Sarcoma

Laurie Graves et al. Curr Treat Options Oncol. 2023 Mar.

Abstract

Over the last decade in soft tissue sarcoma (STS) research, the shifting landscape towards more precise subtype classification and the increasing study of novel therapeutic strategies has prompted a need to highlight current knowledge of effective subtype specific therapies. Undifferentiated pleomorphic sarcoma (UPS), formerly known as malignant fibrous histiocytoma (MFH), is among the most common subtypes of STS arising in the trunk or extremities of adults. Administration of systemic chemotherapy is the primary management in locally advanced and metastatic UPS. While anthracycline-based chemotherapy continues to be standard of care in this setting, outcomes in locally advanced or metastatic UPS remain poor. Recent studies highlight the unique characteristics of UPS that may contribute to its greater sensitivity to immune checkpoint inhibition (ICI) compared to other STS subtypes. With the promise of benefit from novel therapies, including ICI or ICI plus chemotherapy, for a subset of patients with UPS comes the need to identify biomarkers predictive of response to therapy. Ongoing and future clinical trials should place strong emphasis on correlative biomarker studies to learn more about the unique biology of UPS and to identify patients for whom ICI-based therapy will be effective.

Keywords: Checkpoint inhibition; Chemotherapy; Immunotherapy; Soft tissue sarcoma; Systemic therapy; Undifferentiated pleomorphic sarcoma.

PubMed Disclaimer

References

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Crago AM, Cardona K, Koseła-Paterczyk H, Rutkowski P. Management of myxofibrosarcoma and undifferentiated pleomorphic sarcoma. Surg Oncol Clin N Am. 2022;31(3):419–30. https://doi.org/10.1016/j.soc.2022.03.006 . - DOI - PubMed
    1. Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg. 2014;260(3):416–21. https://doi.org/10.1097/SLA.0000000000000869 . - DOI - PubMed
    1. Penel N, Coindre J-M, Giraud A, Terrier P, Ranchere-Vince D, Collin F, et al. Presentation and outcome of frequent and rare sarcoma histologic subtypes: a study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers. Cancer. 2018;124(6):1179–87. https://doi.org/10.1002/cncr.31176 . - DOI - PubMed
    1. Delisca GO, Mesko NW, Alamanda VK, Archer KR, Song Y, Halpern JL, Schwartz HS, Holt GE. MFH and high-grade undifferentiated pleomorphic sarcoma-what’s in a name? J Surg Oncol. 2015;111(2):173–7. https://doi.org/10.1002/jso.23787 Epub 2014 Sep 12. - DOI - PubMed
    1. Doyle LA. Sarcoma classification: an update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone. Cancer. 2014;120(12):1763–74. https://doi.org/10.1002/cncr.28657 . - DOI - PubMed

LinkOut - more resources